Noventra Pharma TZ 60mg Pen 
GLP-1 agonist proven for weight loss. Appetite suppression, fat loss & metabolic support. 
Description
GLP-1 Receptor Activation
binds to GLP-1 receptors, triggering insulin release and glucose regulation.
Appetite Suppression
Slows gastric emptying and increases satiety, leading to reduced caloric intake.
Metabolic Enhancement
Improves insulin sensitivity and promotes fat oxidation for sustained weight loss.
TZ, is a novel investigational medication designed to address the complex challenges of type 2 diabetes mellitus (T2DM). TZ represents an innovative approach to diabetes management, belonging to a class of drugs known as dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists.
In the body, both GIP and GLP-1 are hormones that play crucial roles in regulating blood sugar levels and metabolism. GIP is secreted by the gut in response to nutrient intake and stimulates insulin secretion from pancreatic beta cells. GLP-1 is also released from the gut and acts on pancreatic beta cells to stimulate insulin secretion while simultaneously inhibiting glucagon release, slowing gastric emptying, and promoting satiety. By targeting both of these pathways simultaneously, TZ offers a multifaceted approach to glycemic control in individuals with T2DM.
TZ works by activating GIP and GLP-1 receptors, leading to increased insulin secretion, decreased glucagon release, slowed gastric emptying, and reduced food intake. This comprehensive mechanism of action makes tirzepatide a promising candidate for achieving and maintaining optimal blood sugar levels in patients with T2DM.
Clinical trials evaluating TZ have demonstrated its efficacy in improving glycemic control, as evidenced by reductions in hemoglobin A1c (HbA1c) levels, fasting plasma glucose levels, and body weight. Additionally, TZ has shown a favorable safety profile, with side effects generally being well-tolerated.
TZ has the potential to offer a new treatment option for individuals with T2DM who require additional glycemic control beyond what is achievable with existing medications.
In summary, it represents a promising advancement in the management of T2DM, offering a novel therapeutic approach that targets multiple pathways involved in glucose metabolism. With its dual GIP and GLP-1 receptor agonist activity, it has the potential to improve glycemic control and address unmet needs in the management of T2DM